Clovis Oncology (NASDAQ:CLVS) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Wednesday.

Several other equities analysts also recently commented on CLVS. Cann restated a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, February 27th. Stifel Nicolaus decreased their price target on shares of Clovis Oncology from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Barclays set a $85.00 price target on shares of Clovis Oncology and gave the company a “buy” rating in a research note on Tuesday, February 27th. ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Finally, Oppenheimer restated a “hold” rating on shares of Clovis Oncology in a research note on Wednesday, December 20th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $87.84.

How to Become a New Pot Stock Millionaire

CLVS stock opened at $57.31 on Wednesday. Clovis Oncology has a fifty-two week low of $45.42 and a fifty-two week high of $99.45. The company has a market cap of $2,930.21, a price-to-earnings ratio of -7.65 and a beta of 1.10. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.69 and a quick ratio of 7.35.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($1.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.25. Clovis Oncology had a negative net margin of 624.02% and a negative return on equity of 81.34%. The firm had revenue of $17.04 million for the quarter, compared to the consensus estimate of $19.42 million. During the same period in the previous year, the company earned ($1.83) earnings per share. The company’s quarterly revenue was up 21746.2% on a year-over-year basis. equities research analysts predict that Clovis Oncology will post -4.85 EPS for the current year.

In related news, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $64.97, for a total transaction of $292,365.00. Following the completion of the sale, the director now owns 21,118 shares of the company’s stock, valued at $1,372,036.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $54.09, for a total transaction of $162,270.00. Following the sale, the insider now directly owns 180,571 shares of the company’s stock, valued at approximately $9,767,085.39. The disclosure for this sale can be found here. Insiders have sold 19,500 shares of company stock valued at $1,178,730 in the last ninety days. 12.50% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of CLVS. Commonwealth Equity Services Inc bought a new stake in Clovis Oncology during the third quarter worth about $239,000. First Republic Investment Management Inc. bought a new stake in Clovis Oncology during the third quarter worth about $251,000. BB&T Securities LLC bought a new stake in Clovis Oncology during the third quarter worth about $288,000. Xact Kapitalforvaltning AB bought a new stake in Clovis Oncology during the fourth quarter worth about $328,000. Finally, Greenwood Capital Associates LLC lifted its holdings in shares of Clovis Oncology by 21.6% in the fourth quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 996 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades Clovis Oncology (CLVS) to Strong Sell” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/bidaskclub-downgrades-clovis-oncology-clvs-to-strong-sell/1961489.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.